Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer

Inclusion Criteria: * Histologically documented diagnosis of ovarian cancer, primary peritoneal carcinomatosis or fallopian tube cancer· * Immunohistochemical documentation of c-Kit or PDGFR expression by tumor * At least one measurable site of disease as defined by RECIST or evidence of disease progression by CA125 measurement * Platinum-refractory or platinum-resistant Exclusion Criteria: * No prior exposure to imatinib (Gleevec®) as single agent or in combination * No chemotherapy within 28 days (42 days for nitrosourea or mitomycin-C) prior to being registered to protocol therapy. * No prior radiotherapy to ³ 25 % of the bone marrow * No known brain metastases. * Negative pregnancy test * No current breastfeeding * No investigational agents within 28 days prior to protocol therapy * No prior malignancy in the past 5 years unless the other primary malignancy is not currently clinically significant, nor requiring active intervention, or if other primary malignancy is a basal cell skin cancer or a cervical carcinoma in situ * No severe and/or uncontrolled medical disease (i.e., uncontrolled diabetes, chronic renal disease, or active uncontrolled infection) * No known diagnosis of human immunodeficiency virus (HIV) infection. * No major surgery within 28 days prior to being registered to protocol therapy. * No refractory ascites requiring drainage more frequently than once a month * No presence of clinically significant small bowel obstruction * No prior exposure to docetaxel (exposure to paclitaxel is allowed) * No parenteral nutrition within 28 days prior to being registered to protocol therapy. * No concomitant treatment with potent CYP 3A4 inhibitors (i.e., ketoconazole) is permitted during therapy on this protocol. * No therapeutic anticoagulation with warfarin while on study (use of low molecular weight heparin is allowed, if necessary). * No peripheral neuropathy \> grade 1 * No history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80. * No serious concomitant systemic disorders incompatible with the study * No prior malignancies with the exception of curatively treated basal or squamous carcinoma of the skin, carcinoma in-situ of the cervix, or any other cancer for which the patient has been disease-free for \< 5 years.